Yeah, lot of effort to produce a 92% to 99% stock price decline and near total loss for your investors and wipe out of common share holders and burn though how much paid in capital w/o a single approved product, no major finance partner (non dilutive) willing to take you on for 4 yrs now, your major trials now 5 yrs old and going nowhere essentially, using ASHER and similar desperation funding qtr after qtr, diluting away your common shareholders to pretty much nothing - as in a doubling of the outstanding shares in about a yr to now almost 600 million fully diluted on a sub 3 penny stock, several past defaults on major loans, paying everything from accounts payable to anyone such as "services rendered" in common stock dilutive shares, borrowing and loaning constantly from insiders and other such as "related party transactions" in all kinds of screwy deals typically paid-off in common shares by reading the 10-K or 10-Q filings to keep afloat while you substantially increase your own pay, all while you get paid handsomely and get bonuses and options tacked on as sweeteners. Real bummer. Sure. Nice gig IMO.
Producing a sub 3 cent stock price (with a 6/10ths of a cent low in Dec 2013) is a real piece of "work" and "effort" IMO. A market cap barely equal to your current debts, yeah. Operational losses with no end in site. Nearly no cash at the end of the qtr as is typical, maybe $90K left, and did any major trial advance or get one iota closer to an FDA approval? Not IMO. Real bummer. Yeah, sounds like bonus reward time to me, why not? Real bang up performance.
What "positive results"?? Just curious?
